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370Objective: The study objective was to evaluate the safety and efficacy of sutureless self-expanding nitinol stent-
frame aortic valve prostheses made of equine pericardium implanted in patients with symptomatic aortic valve
disease.
Methods:We performed a retrospective analysis of 120 patients (mean age, 76.7  5.9 years) who underwent
isolated aortic valve replacement or in combination with other cardiovascular procedures. Preoperatively, Soci-
ety of Thoracic Surgeons score was determined. Transthoracic echocardiography and clinical outcome evalua-
tion were performed at the time of discharge and at 6, 12, and 18 months follow-up, respectively.
Results:A total of 71 of 120 patients underwent isolated sutureless aortic valve replacement (mean aortic cross-
clamp time, 37 11 minutes; mean bypass time, 62 18 minutes). Coronary bypass grafting was performed in
30 patients. Overall mean Society of Thoracic Surgeons score was 14.8% 10%. Thirty-day mortality rate was
6.7% overall and 1.4% in stand-alone procedures. During a mean follow-up of 313 days, 3 more deaths oc-
curred. The reoperation rate was 4.2%. Mean and peak transvalvular pressure gradients were 9 mm Hg (4-13
mm Hg) and 14 mm Hg (8-22 mm Hg) at discharge, respectively. In 8 patients (6.7%), permanent pacemaker
implantation was necessary. No thromboembolic events or bleedings related to the bioprosthesis were observed.
Conclusions: In this large single-center experience with sutureless aortic valve replacement, the surgical pro-
cedure is shown to be safe and time-saving. In view of the excellent hemodynamic results and shortening of aor-
tic crossclamp and bypass times, we notice advantages especially in high-risk patients. Minimally invasive
access seems to be facilitated. The long-term durability of this prosthesis has yet to be determined. (J Thorac
Cardiovasc Surg 2014;147:370-5)Despite the recent introduction of various alternative ap-
proaches, surgical treatment of the aortic valve represents the
gold standard of treatment in case of severe and symptomatic
valve disease. This is also proven for various patientswithmul-
tiple comorbidities and high perioperative risk, for example,
older patients and patients with a distinct prosthesis–patient
mismatch.1-3 Various surgical approaches to enhanced
treatment of the diseased aortic valve have been developed
in the last decade, ranging from aortic valve repair to
stentless prosthesis and complex aortic root surgery.4-6
Numerous studies have shown pressure gradients across
the implanted prosthesis to be crucial for mass regression
and restoration of left ventricular function and, conse-
quently, long-term survival.7,8 Stentless substitutes have
been shown to be surgically more challenging but result
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The Journal of Thoracic and Cardiovascular Surgorifice area and omission of the obstructive elements of
the stented bioprosthesis. In this context, the replacement
of the aortic valve with a sutureless prosthesis held in
place by radial forces represents an interesting idea. The
symmetric pericardial prosthesis is mounted onto a nitinol
frame, which guarantees optimal orientation because of
its memory effect.9 This new technique offers complete re-
moval of the diseased aortic valve and calcifications under
vision in combination with avoiding placement and tying
of sutures in the aortic annulus, facilitating minimally inva-
sive access, decreasing surgical trauma, and providing he-
modynamic benefits through its unique design.
Various reports have been published on the initial experi-
ence in relatively small cohorts of selected patients, mostly
with isolated aortic valve stenosis.10-12 The current study
reports on the largest single-center experience in sutureless
implantation of the Enable aortic bioprosthesis (Medtronic,
Inc, Minneapolis, Minn) in unselected patients with respect
to their clinical outcome and hemodynamic performance
for up to 18 months postoperatively.MATERIALS AND METHODS
Patients
Between July 2010 and March 2012, 120 patients were included in this
study. Inclusion criteria were severe, symptomatic aortic valve disease,
New York Heart Association function class II or higher, and scheduled
for surgical valve replacement. All patients gave written informed consentery c January 2014
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
TEE ¼ transesophageal echocardiography
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Table 1.
Sutureless Aortic Valve Prosthesis
The Enable sutureless aortic prosthesis consists of 2 main parts: the
original stentless 3F biological valve made of equine pericardium with 3
symmetric sinuses that are incorporated into a nitinol stent frame. This ma-
terial returns to its original shape when it is exposed to body temperature
while maintaining the correct orientation of the pericardial leaflets.
Operative Technique
Cardiopulmonary bypass and cardioplegic arrest are established in routine
fashion after median or partial sternotomy. In selected patients with a mini-
mally invasive approach, a small right anterolateral minithoracotomy approx-
imately 7 cm in length is performed and cannulation for cardiopulmonary
bypass is installed via femoral cannulation. Because of the height of the nitinol
stent of the prosthesis, a transverse aortotomy at least 3.5 cm above the origin
of the ostium of the right coronary artery is mandatory. The diseased native
aortic leaflets are excised carefullywithout injuring the annulus. Precise sizing
of the aortic annulus is crucial. The prosthesis chosen is then rinsed for 30 sec-
onds 3 times before placing it into ice-cold water. When malleable, the pros-
thesis iswrappedarounda plastic bar andmounted onto a cross-action forceps.
A double-armed 4-0 polypropylene suture is placed into the nadir of the
noncoronary sinus and the corresponding site at the upper flange of theEnable
ring. The folded Enable prosthesis is then positioned into the aortic annulus
supported by the guiding suture. After removal of the forceps, the stent is un-
folded and aligned to the remaining aortic annulus. Meticulous and precise
placement of the valve prosthesis along the aortic annulus is absolutely man-
datory for successful deployment. Correct positioning is verified followed by
applicationofwarmwater causing the nitinol stent to regain its original shape.
After weaning from cardiopulmonary bypass with cannulas still in
place, transesophageal echocardiography (TEE) is performed to evaluate
correct positioning of the prosthesis and to exclude paravalvular leakage.
In patients with concomitant cardiac procedures, placement of the Enable
prosthesis is performed as the last procedure.
Follow-up
All data related to the clinical outcome of the patient and the perfor-
mance of the Enable prosthesis were collected. Thereby, adverse events
were divided into early (within 30 days postoperatively) and late complica-
tions (after 30 days).
Before discharge, every patient underwent investigation of the Enable
prosthesis by 2-dimensional transthoracic echocardiography. Hemody-
namic parameters, such as transvalvular peak and mean pressure gradients,
and effective orifice area were determined; these echocardiographic exam-
inations were repeated 6, 12, and 18 months after surgery, respectively.
Statistical Analysis
For general demographic, clinical, and operative data, descriptive
statistical methods were used and expressed as mean standard deviation.
Categoric variables are presented as numbers with percentages.RESULTS
Of the 120 patients, the majority was male (81/120;
67.5%). The mean age at the time of implantation wasThe Journal of Thoracic and Ca76.7  5.9 years (range, 64-90 years). More than 90% of
the patients were in New York Heart Association class III
and IV. The foremost cause for valve replacement was se-
vere stenosis due to degenerative or rheumatic valve disease
(110/120; 91.7%). Ten patients presented with severe pure
aortic insufficiency as the underlying valve pathology. In 3
of these patients, valve replacement was necessary because
of acute and subacute endocarditis. Detailed patient demo-
graphics are depicted in Table 1.
The overall study patients’ mean logistic European Sys-
tem for Cardiac Operative Risk Evaluation was 20.71%
(range, 2%-90%), and the mean Society of Thoracic Sur-
geons score was 14.78% (range, 2%-76%) for overall pre-
dictive mortality. However, for patients with isolated aortic
valve replacement (AVR) the predictive risk scores were
slightly lower (16.3% and 12.1%, respectively) (Table 2).
Isolated implantation of the Enable prosthesis in the aor-
tic position was performed in 71 patients (59.2%). Al-
though two thirds of those underwent a full sternotomy,
a less-invasive approach was chosen in the remaining pa-
tients undergoing isolated AVR: partial sternotomy
(n ¼ 20) or anterolateral minithoracotomy (n ¼ 4) in se-
lected patients.
A total of 49 patients underwent concomitant surgical
procedures, with coronary bypass surgery being the most
frequent (30/49; 61.2%). The number of bypass grafts
ranged from 1 to 4 arterial and venous grafts per patient.
The remaining patients in the concomitant group (19/49 pa-
tients; 38,8%) underwent various concurrent surgeries,
listed in Table 3.
In the isolated AVR group, mean cardiopulmonary by-
pass time was 62  18 minutes (range, 39-141 minutes)
and mean crossclamp time was 37  11 minutes (range,
18-69 minutes). In the group of patients who underwent
concomitant procedures, crossclamp and bypass times
were mainly dependent on the extent of the additional pro-
cedures and were on average 47  19 minutes (range, 18-
134 minutes) and 80 39 minutes (range, 39-322 minutes),
respectively.
All available valve sizes were implanted in patients in
this study, with the majority of patients receiving a 23- or
25-mm valve. The valve size distribution was as follows:
19 mm (n ¼ 2), 21 mm (n ¼ 18), 23 mm (n ¼ 48), 25
mm (n ¼ 32), 27 mm (n ¼ 18), and 29 mm (n ¼ 2).
A repeat aortic crossclamping was necessary intraopera-
tively in 10 patients because of paravalvular leakage (n¼ 7)
and acute migration into the left ventricle (n¼ 2) or into the
ascending aorta (n¼ 1) assessed by TEE while cannulas for
cardiopulmonary bypass were still in place (Table 4). In pa-
tients with intraoperative paravalvular leakage (n ¼ 7), the
reasons for repeat crossclamping of the aorta were incorrect
size in 3 patients and irregular annulus (ie, significantly dif-
ferent size and level of the 3 sinuses) in 4 patients, leading to
improper positioning. A different size of the same type ofrdiovascular Surgery c Volume 147, Number 1 371
TABLE 1. Preoperative patient characteristics
No. of patients 120 (male, 67.5%)
Mean age 77 y (64-90 y)
Logistic euroSCORE (mean) 20.7%  19%
STS score (mean) 14.8%  10%
BMI 27.8%  4.7%
Ejection fraction 55%  11%
NYHA class
II 11/120 (9.2%)
III 93/120 (77.5%)
IV 16/120 (13.3%)
Risk factors
Pulmonary hypertension 54/120 (45%)
Carotid artery disease 34/120 (28.3%)
Stroke 12/120 (10%)
Atrial fibrillation 28/120 (23.3%)
Endocarditis 3/120 (2.5%)
Diabetes (under medication) 27/120 (22.5%)
Dialysis 3/120 (2.5%)
Chronic lung disease 16/120 (13.3%)
Dyslipidemia 81/120 (67.5%)
Pulmonary hypertension ¼ pulmonary artery pressure greater than 25 mm Hg or in-
direct echocardiographic findings, such as dilatation or impairment of the right ven-
tricle function. Carotid artery disease ¼ stenosis of internal carotid artery of 50% or
greater. Chronic lung disease ¼ patients under long-term medication for chronic
bronchitis or emphysema and pathologic pulmonary function test. euroSCORE,
European System for Cardiac Operative Risk Evaluation; STS, Society of Thoracic
Surgeons; BMI, body mass index; NYHA, New York Heart Association.
TABLE 3. Surgical procedures
Overall Enable (Medtronic, Inc,
Minneapolis, Minn) implantations
120
Isolated AVR 71
 Redo AVR 2
 Redo after CABG 2
Concomitant cardiovascular procedures 49
 AVR þ CABG 30
 AVR þ atrial ablation 9
 AVR þ ASD closure 2
 AVR þ myotomy/myectomy 1
 AVR þ MVR 3
 AVR þ TVR 1
 AVR þ pericardectomy 1
 AVR þ ascending/arch aortic surgery 2
AVR, Aortic valve replacement; CABG, coronary artery bypass grafting; ASD, atrial
septal defect; MVR, mitral valve repair; TVR, tricuspid valve repair.
TABLE 4. Clinical outcome and adverse effects
Mortality
Early 8/120 (6.7%)
Late 3/112 (2.7%)
Repeat aortic crossclamp 10 (8.3%)
 Prosthesis migration 3
 Paravalvular leakage 7
Rethoracotomy 4 (3.3%)
MI 0
Thromboembolism* 1 (0.8%)
Stroke 1 (0.8%)
Pneumonia 4 (3.3%)
Acquired Cardiovascular Disease Eichstaedt et al
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Dsutureless prosthesis was implanted in 3 patients. New
proper positioning was sufficient in the remaining patients;
in 2 of them it was secured by adding another stitch to se-
cure the positioning in the annular level. Retrospectively,
the wrong size was causing valves to migrate into the left
ventricle or ascending aorta after termination of cardiac ar-
rest. In 2 patients with pure aortic insufficiency, the suture-
less prosthesis slid into the left ventricle after restoring
contractions and filling it with blood with consecutive ex-
tension of the elastic annulus. They were exchanged with
a larger size of the sutureless valve prosthesis. In 1 patient,
the prosthesis was placed too high and slid into the ascend-
ing aorta during manipulation of the heart for bleeding con-
trol. It was repositioned and secured with 2 guiding stitches
tied down.TABLE 2. Risk of mortality and outcome
Isolated AVR
STS score 12.1% (range, 1.6%-34.9%; SD, 5.8%)
Logistic euroSCORE 16.3% (range, 2.1%-69%; SD, 12.6%)
30-d mortality 1/71 (1.4%)
Overall mortality 2/71 (2.8%)
Concomitant surgery
STS score 19% (range, 6.5%-75.9%; SD, 13.2%)
Logistic euroSCORE 27.3% (range, 2.9%-90.3%; SD, 24.2%)
30-d mortality 7/49 (14.3%)
Overall mortality 9/49 (18.4%)
AVR, Aortic valve replacement; STS, Society of Thoracic Surgeons; euroSCORE,
European System for Cardiac Operative Risk Evaluation; SD, standard deviation.
372 The Journal of Thoracic and Cardiovascular SurgThe accumulated follow-up time was 93.5 patient-years
in total. The mean follow-up time was 313 days until March
2012. The mean hospital stay was 9 days (range, 3-89 days).
Follow-up was complete in 95% of patients.
The overall 30-day mortality rate was 6.7% (8/120
patients; Table 4). There was 1 intraoperative death due to
fatal tearing of the thoracic aorta during intraaortic balloon
insertion in an patient with coronary artery disease and pre-
operative low output syndrome. One patient in the isolated
AVR group died in the early postoperative period after
unsuccessful resuscitation (1.4%). In the group withRenal failure 3 (2.5%)
Permanent pacemaker 8 (6.7%)
Prosthetic endocarditis 2 (1.7%)
Structural valve deterioration 0
Major pVL 2 (1.7%)
Iatrogenic valve dislocation 1 (0.8%)
Minor pVL 4 (3.3%)
Reoperation 5 (4.2%)
Mean length of hospital stay 7.9 d
Late mortality ¼ after hospital discharge, rethoracotomy due to significant bleeding.
Minor pvL ¼ aortic insufficiency 0 to 1 degrees or trivial regurgitation. Major
pvL ¼ aortic regurgitation greater than grade I. MI, Myocardial infarction; pVL,
paravalvular leakage. Early mortality ¼ hospital or 30-day mortality. *This patient
had heparin-induced thrombocytopenia postoperatively, and disseminated emboli
developed in both feet.
ery c January 2014
FIGURE 1. Mean pressure gradient according to various prosthesis sizes
during follow-up.
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cantly higher (14.3%), expressing the clinical outcome of
the preoperative risk assessment (Table 2).
In the late postoperative period, 3 patients died. Of those,
2 high-risk patients (1 of the isolated AVR group) developed
a complex postoperative course leading to intractable septic
multiorgan failure (days 31 and 48). Another patient with
concomitant coronary bypass grafting died at home of an
unknown reason after 82 days. In those patients who died
during the observation period, the corresponding logistic
European System for Cardiac Operative Risk Evaluation
and Society of Thoracic Surgeons scores were a mean
51.4% and 15.3% for isolated AVR and 45.6% and 40%
for concomitant cardiac surgeries, respectively.
As shown in Table 4, the reoperation rate was 4.2% (5/
120 patients). Replacement of the Enable prosthesis took
place on days 5, 21, 35, 52, and 105 after the implantation
procedure. The earliest reoperation took place in a patient
in whommanipulation at the aortic root had to be performed
to control bleeding from the aortotomy site during a rethor-
acotomy. This caused an active extraction of the prosthesis
from its annular position because of interference with the
nitinol stent by placement of a suture accidentally through
the nitinol stent, leading to upward traction. After repeat
aortic crossclamp to reposition the Enable prosthesis cor-
rectly, a major paravalvular leakage occurred in 1 patient
during the postoperative course, requiring a reoperation.
Another patient had prosthetic endocarditis and systemic
septic impairment. In 2 other patients, the underlying aortic
valve pathology revealed a pure aortic insufficiency. A ma-
jor paravalvular leakage was discovered by echocardiogra-
phy examination soon after the operation and deteriorated
further. In all reoperated patients, an uncomplicated ex-
change with a nonsutureless type of prosthesis was per-
formed with no mortality. The explanted Enable valve
was carefully examined but did not show any structural de-
fect or thrombotic formations.
Permanent pacemaker therapy after Enable implantation
was necessary in 8 patients postoperatively (6.7%) because
of newly developed arrhythmia. There was no difference
between patients with isolated AVR or concomitant cardiac
procedures (7% vs 6.1%).
At the time of discharge, transthoracic echocardiogram re-
vealed peak pressure gradients of 14.9  4.5 mm Hg, mean
pressure gradients of 8.6 2.8 mmHg, and aortic valve area
of mean 2.5 0.9 cm2. During 6- and 12-month follow-ups,
the pressure gradients remained constant. Peak pressure was
16 5.1 mmHg and 16.5 5.8 mmHg, and mean pressure
was 9.3  3.6 mm Hg and 9.5  3.8 mm Hg at 6 and 12
months, respectively (Figure 1). Mean aortic valve area
had decreased at the same time period to 2.2  0.8 cm2.
Examination by echocardiography at the time of dis-
charge detected 4 trivial paravalvular leakages, which had
not appeared intraoperatively and remained stable duringThe Journal of Thoracic and Cafollow-up without any clinical impairment and signs of
hemolysis.DISCUSSION
Adequate treatment of patientswith severe aortic valve dis-
ease remains challenging for both interventional and surgical
approaches. Despite the progressive development of trans-
catheter aortic valve interventions, the midterm data are not
convincing. ThePARTNER trial (cohortsA andB) has shown
some benefit in patients assigned as inoperable, but medical,
ethical, and financial concerns are raised.13,14 It is a constant
methodical risk for mortality and morbidity that the usually
heavy calcified leaflets and annulus are pushed aside,
causing a high incidence of embolic events. Furthermore,
the results remain questionable in many cases;
calcifications still in place are causing an incomplete
attachment to the annulus and, consecutively, paravalvular
leakages of higher degree in up to 70% of cases.15,16
The sutureless implantation technique represents a novel
development in innovative surgical AVR. The possibility of
avoiding multiple stitches at the (potentially calcified)
aortic annulus ensures less traumatic surgery at the aortic
root, eventually causing less embolic complications. In
fact, embolic complications in this study were rare. Insuffi-
cient peripheral vascular perfusion due to heparin-induced
thrombocytopenia developed in only 1 patient with postop-
erative septic complications. Our anticoagulation protocol
after sutureless valve implantation consists of clopidogrel
for 6 weeks and long-term low-dose aspirin based on rec-
ommendations for patients with carotid artery stenting.17
Administration of a vitamin K antagonist is avoided if no
other indications apply.
The absence of suturing offers the potential for reducing
aortic crossclamp and total cardiopulmonary bypass time.
We were able to slightly decrease our implantation times,
as did Aymard and colleagues.10 In a multicenter study,
Martens and colleagues9 reported on mean crossclamp
times of 58  25 minutes, although it is unclear whetherrdiovascular Surgery c Volume 147, Number 1 373
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ideal situation, aortic crossclamp times less than 20 minutes
are feasible.
In our experience, sutureless aortic valve implantation of-
fers potential advantages in high-risk patients or for those
with concomitant procedures. The overall mean aortic
crossclamp time in our group was 47 19 minutes, consid-
ering the fact that 41% underwent additional partly exten-
sive cardiac procedures (Table 2).
On the other hand, correct positioning of the prosthesis can
be time-consuming and must be carried out accurately. The
question of whether any paravalvular leakage, observed by
intraoperative TEE,must be corrected or not, is controversial.
It is doubtless that a clearly visible paravalvular leakage at the
time of surgery demands immediate correction.
In our series, the incidence of repeat crossclamp of the
aorta to reposition the sutureless prosthesis because of im-
mediate paravalvular leakage was 8.3%. This represents
a unique feature in this novel surgical approach for AVR.
It confirms the necessity of precise sizing, which is difficult
in specific constellations, such as pure aortic insufficiency
and irregular length and level of the sinuses. In critical
cases, single stay stitches may be used to avoid migration
from the aortic annulus and consecutive paravalvular leak-
age. In our experience, repeat crossclamp to correct pros-
thesis misplacement did not result in a worse outcome or
extensive prolongation of operating times. Therefore, it is
our policy that no patient leaves the operating room without
a perfect echocardiographic result, that is, there is no accep-
tance of any paravalvular leak.
We have observed a favorable outcome in patients who
underwent isolated AVR with an overall mortality of
2.8% during the observation period of up to 20 months, al-
though the predictive mortality has been significantly
higher. In total, 11 patients (9.2%) died in our study, mainly
in the high-risk group with concomitant cardiac procedures.
In the European multicenter study that included 30% of
nonisolated AVR cases, the overall mortality was 12.9%.
Unfortunately, predictive risk scores and detailed informa-
tion on both patient groups have not been provided.9 Ay-
mard and colleagues10 reported on a 30-day mortality of
3.5% in 28 patients with stand-alone sutureless AVR but
observed an overall 1-year mortality of 13.8%. Because
the Enable bioprosthesis has been proven to show persistent
excellent hemodynamic results (Figure 1), other non–valve-
related factors (eg, age and comorbidities) account for
higher mortality rates during long-term follow-up.
In an extensive analysis, Matthews and colleagues18 re-
ported on an incidence of postoperative pacemaker implan-
tation after conventional AVR between 3.0% and 11.8%.
Actual single-center experience is approximately 8.2%
according to Dawkins and colleagues.19 Aymard and col-
leagues10 reported on the requirement of pacemaker therapy
in patients after sutureless AVR in more than 18%, whereas374 The Journal of Thoracic and Cardiovascular SurgMartens and colleagues20 have reported on only 1 pace-
maker implantation in their patient group with partial ster-
notomy access (4.5%). In our study, only 1 of 24 patients
with a less-invasive approach (4.2%) received postopera-
tive pacemaker therapy; the overall incidence was 6.7%.
We could not ascertain a logical reason for the higher pace-
maker incidence compared with those who underwent con-
comitant procedures other than the radial forces of the
nitinol stent. Technically, decalcification of the annulus
did not differ between the patients.
In general, access to the aortic valve via partial sternotomy
or right anterior minithoracotomy has evolved in recent
years.21,22 The sutureless valve implantation represents
a further step toward true minimally invasive cardiac
surgery. In principle, the folded bioprosthesis mounted onto
a forceps or a delivery device in general is implantable
through limited access, as others have already shown in
smaller patient groups.20,23 In our experience, Enable
implantation via partial sternotomy results in good outcome
and no surgical impairment. In contrast, access via lateral
minithoracotomy may be limited by proper instrumentation,
requiring further development of surgical tools.
A major advantage of the Enable prosthesis is the broad
spectrum of sizes available. Especially in smaller diameters
from 19 to 23 mm, the advantages of the superior hemody-
namics become evident. To avoid patient–prosthesis size
mismatch, aortic root enlargement or replacement is usually
necessary at clearly greater risk.24 Borger and colleagues25
reported on the superiority of stentless aortic bioprosthesis
in terms of hemodynamic results and, consequently, left
ventricular mass reduction, with some evidence of im-
proved survival in comparison with patients who received
stented aortic valves. In their study, the overall mean pres-
sure gradients were mean 11  5 mm Hg in the stentless
valve group. In our experience, the low-pressure gradients
even in small prosthesis sizes of 21 mm (compare with
Figure 1) and constant mean pressure gradients between
12 and 14 mm Hg within the first 18 months demonstrate
the excellent hemodynamic profile of the Enable prosthesis.
The overall mean pressure gradients were lower with 8.6
mmHg on average at the time of discharge, slightly increas-
ing at 12 months follow-up to 9.5 mm Hg.
From a surgical standpoint, the higher level of aortotomy
with respect to the nitinol stent may lead to certain discom-
fort initially. Otherwise, there has not been a published case
with impaired coronary blood flow due to ostia obstruction.
This can be attributed to the more meticulous positioning at
the aortic annular level but is also due to design of the pros-
thesis itself: Expansion of the leaflets is limited to the di-
mension of the nitinol frame. In context with sutureless
valve therapy, the nitinol stent is not only thinner but also
hardly influences the left outflow tract. Nevertheless, spe-
cific attention is necessary for exact sizing because the pros-
thesis is fixed by radial forces of the nitinol frame at theery c January 2014
Eichstaedt et al Acquired Cardiovascular Diseaseannular level only. This feature allows for use of this partic-
ular prosthesis with slight post-stenotic dilatation, too.
CONCLUSIONS
This single-center experience in sutureless aortic valve
implantation represents an innovative surgical treatment
for patients with severe aortic valve disease, resulting in ex-
cellent persistent hemodynamic conditions. The implanta-
tion procedure is safe and surgically effective for AVR.
We believe the spectrum of indications for use of the suture-
less valve to be broad, but certainly more experience with
long-term follow-up will be necessary to verify the durabil-
ity and safety of the valve prosthesis. We see advantages of
the sutureless approach in underlying patient–prosthesis
size mismatch, severely calcified aortic roots in high-risk
patients, and potentially in true minimally invasive surger-
ies. The procedure can be time-saving and advantageous
in extensive surgery and high-risk patients.A
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